obesity treatment with bariatric surgery vs glp-1 receptor agonists Medication vs. for Weight Loss: Options Matter Association between plausible genetic factors

Ghezzawi, M

Rates of obesity nearly doubled between 1980 and 2008 worldwide, and more than half of all adults in the OECD region are now overweight, with 18% considered obese

Based on the application, the global GLP-1 receptor agonist market is segmented into different categories such as type 2 diabetes, obesity, and others

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care

PLoS One (2009) 4(3):e4962

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors